MonoSolRx LLC Enters Into a License and Collaboration Agreement With Adams Respiratory Therapeutics

WARREN, N.J., MARCH 27 /PRNewswire/ -- MonoSolRx, LLC, the Warren, New Jersey based leading pharmaceutical oral thin film company announced today that it had entered into a license and collaboration agreement with Adams Respiratory Therapeutics, Inc . MonoSolRx will use its rapid dissolve oral thin film drug delivery platform to develop prescription and over-the-counter (OTC) products for Adams.

Commenting on the agreement, President and Chief Executive A. Mark Schobel said, "This agreement, with a market innovator and leader like Adams, validates the strength of our technology, development capabilities, manufacturing capacity and approach to partnering. Oral thin film has broad application in the prescription pharmaceutical market. We are very excited about the partnership with Adams."

Adams Chief Operating Officer Robert D. Casale said, "Currently, there are no prescription respiratory products that employ this unique thin film delivery technology, and we believe there are several product targets that would benefit from the application of this technology."

Under the terms of the agreement MonoSolRx provides an exclusive, royalty bearing, non-transferable license to use its proprietary thin film drug delivery technology to develop and market two or more respiratory products in North America. The initial prescription product has been identified but not yet disclosed. Adams also has the right of first refusal to develop a limited number of additional high value prescription candidates in the respiratory space. Under a separate product supply agreement, MonoSolRx has agreed to manufacture and supply finished products that result from the collaboration.

MonoSolRx is responsible for completing the product development work and will be eligible to receive payments for completing certain pre-defined development milestones. Adams will be responsible for performing all aspects of clinical development and regulatory submission as well as marketing and distribution. Financial terms of the agreement are not being disclosed.

MonoSolRx is a thin film drug delivery company specializing in proprietary dissolving thin film products. Our thin film drug delivery dosage form is similar in size, shape and thickness to a postage stamp and dissolves readily on the tongue for easy use by patients. Our thin film drug delivery technology is now used in the over-the-counter, or OTC, marketplace and is currently emerging in the prescription drug market.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

Forward-Looking Statements

This press release contains certain "forward-looking" statements, including the Company's future financial performance and growth. Such forward- looking statements can be identified by the words "believes," "anticipates," "expects," and similar expressions and are subject to risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.

CONTACT: Investor - Media: A. Mark Schobel, +1-732-564-5000, or BusinessDevelopment and Licensing: Joseph Fuisz, +1-202-223-1827, both ofMonoSolRx, LLC

Web site: http://www.monosolrx.com/